Study Suggests Alternative to Common HCV Treatment with Equally High SVR, No PPI Modification Needed

Share
  • Twitter
  • Facebook
  • email
  • StumbleUpon
  • Delicious
  • Google Reader
  • LinkedIn
  • Google Bookmarks

     

    Mitchell L. Shiffman, MD, FACG

    Mitchell L. Shiffman, MD, FACG

    Poster 413 Efficacy of Ombitasvir/Paritaprevir/ and Dasabuvir +/-Ribavirin in Patients Receiving Concomitant Acid-Reducing Agents in Phase 3 Trials

    Author Insight from Mitchell L Shiffman, MD, FACG, Director, Liver Institute of Virginia, Bon Secours Health System

    What’s new here and important for clinicians? 

    The most common treatment for patients with chronic HCV is Harvoni (sofosbuvir/ledipasvir).  The absorption of this anti-viral combination is affected by gastric pH and reduced in less acidic gastric environments.  Thus, the dose of anti-acid drugs must be limited in patients taking PPIs, H2 blockers and even oral antacids.  Limiting acid suppression in patients with severe dyspepsia, severe GERD and Barretts esophagus could be problematic in some patients with HCV who require anti-viral treatment.  This study has demonstrated that acid suppression does not affect the efficacy of patients with HCV being treated with Veikkira Pak.

    What do patients need to know?   

    That there is an alternative to treatment with equally high SVR rates where acid suppression does not need to be modified.

    Read Abstract

    Author Contact Mitchell L Shiffman, MD, FACG, Director, Liver Institute of Virginia, Bon Secours Health System

    mitchell_shiffman@bshsi.org


    Media Interview Requests:

    To arrange an interview with any ACG experts or abstract authors please contact Jacqueline Gaulin of ACG via email jgaulin@gi.org or by phone at 301-263-9000.

    Share
    • Twitter
    • Facebook
    • email
    • StumbleUpon
    • Delicious
    • Google Reader
    • LinkedIn
    • Google Bookmarks